Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPER-RESET
NCT07607197Phase 2Recruiting
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Feb 2024
- Primary completion
- May 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous CD34+ cells in Human Leukocyte Antigen Sensitization, sponsored by Vall d'Hebron Research Institute. Started Feb 2024; status: recruiting.
02
Drugs
autologous CD34+ cells
03
Conditions
Human Leukocyte Antigen Sensitization
Beyond the preview
Go deeper on NCT07607197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607197.